Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397911 · ClinicalTrials.gov registry record · Phase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Oneness Biotech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT06397911 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Oneness Biotech Co.. The registered enrollment target is 90 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The trial reports 16 study locations across 3 states.
The verdict
NCT06397911, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Oneness Biotech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FB825
Study Locations (16)
Other
- Kaohsiung Chang Gung Memorial Hospital - Kaohsiung City
- Kaohsiung Veterans General Hospital - Kaohsiung City
- Linkou Chang Gung Memorial Hospital - New Taipei City
- Taipei Medical University-Shuang Ho Hospital - New Taipei City
- China Medical University Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
- Taipei Mackay Memorial Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
- Tri-Service General Hospital - Taipei
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research, Inc. - Fremont
- California Allergy and Asthma Medical Group - Los Angeles
- University of California, Davis Health, Department of Dermatology - Sacramento
Texas
- UT Health Science Houston - Bellaire
- Center for Clinical Studies - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06397911
The ClinicalTrials.gov registry entry for NCT06397911 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The listed sponsor is Oneness Biotech Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06397911 reports 16 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06397911 about?
NCT06397911 is a clinical study titled "Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis". This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
What is the current status of trial NCT06397911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-08-08. Estimated completion is 2026-06-30.
What conditions does trial NCT06397911 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06397911?
The interventions under investigation include: Placebo (DRUG), FB825 (DRUG).
Who is sponsoring clinical trial NCT06397911?
This trial is sponsored by Oneness Biotech Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06397911 being conducted?
This trial has 16 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.